publication date: Dec. 1, 2017

In Brief FDA’s Pazdur named to Bloomberg 50 list

Richard Pazdur, director of the FDA Oncology Center of Excellence, was named to the Bloomberg list of 50 people who defined global business in 2017.

This year, FDA for the first time approved the first site-agnostic indication for a cancer drug. The agency also approved two CAR-T cell therapies.

In an interview with Bloomberg, Pazdur said his experience as a caregiver influenced his approach to drug regulation.

“My wife’s demise in 2015 from ovarian cancer put an urgency in me to get out effective therapies,” Pazdur said to a Bloomberg reporter. “I would leave Mary at 8 a.m. and come back at 6 p.m., and she would not have moved because she was so fatigued by her treatment. We’re now working to bring a patient assessment of toxicity into product labeling.”

In a separate development, the inaugural Mary Pazdur Award for Excellence in Advanced Practice in Oncology was announced at the 2017 conference of the Journal of the Advanced Practitioner in Oncology.

The award honors Mary Pazdur for her contribution as an advanced practitioner to the field of oncology and to the development of the journal. Additional information about the award is posted here.


National Academies report … Continue reading FDA’s Pazdur named to Bloomberg 50 list

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.